echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Nivolumab in combination with docetaxel for advanced or recurrent NSCLC

    Clin Cancer Res: Nivolumab in combination with docetaxel for advanced or recurrent NSCLC

    • Last Update: 2022-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The addition of cytotoxic chemotherapy to immune checkpoint inhibitor (ICI) therapy may enhance antitumor effects


    Taniguchi et al.


    The primary endpoint of the phase III study portion was overall survival (OS), and secondary endpoints included progression-free survival (PF), overall response rate (ORR), and toxicity


    Overall survival in both groups

    A total of 128 patients (64 in each group) were included in the overall analysis cohort (FAS)



    Hematological and gastrointestinal adverse events were more common in arm


    In conclusion, the addition of docetaxel to nivolumab significantly prolonged OS and PFS in previously ICI-naïve NSCLC patients despite a slight increase in toxicity


     

    Original source:

    Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.